Christian Brander Selected Research

Epitopes

1/2020	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
5/2019	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
1/2018	Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B27:05- and -B27:02-Mediated Control of HIV-1 Infection.
11/2015	Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function.
11/2014	Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.
5/2014	HIV subtype influences HLA-B*07:02-associated HIV disease outcome.
6/2013	Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients.
12/2012	Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope.
1/2011	A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais.
1/2010	Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christian Brander Research Topics

Disease

49	Infections 12/2022 - 02/2002
29	HIV Infections (HIV Infection) 01/2022 - 12/2002
17	Viremia 11/2022 - 03/2004
12	Disease Progression 01/2018 - 12/2004
8	Virus Diseases (Viral Diseases) 01/2020 - 12/2002
4	Acquired Immunodeficiency Syndrome (AIDS) 05/2020 - 11/2007
4	Human Influenza (Influenza) 06/2013 - 04/2004
3	Inflammation (Inflammations) 01/2019 - 12/2004
3	Vaccinia 01/2015 - 09/2006
3	Persistent Infection 06/2012 - 09/2006
3	Neoplasms (Cancer) 03/2012 - 06/2004
2	COVID-19 01/2022 - 08/2020
2	Communicable Diseases (Infectious Diseases) 11/2020 - 01/2019
2	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2017 - 02/2013
2	Hypersensitivity (Allergy) 06/2013 - 12/2012
2	Chronic Hepatitis B 02/2013 - 01/2013
2	Kaposi Sarcoma (Kaposi's Sarcoma) 09/2009 - 06/2007
2	Epstein-Barr Virus Infections 11/2005 - 12/2002
1	Body Weight (Weight, Body) 12/2021
1	Disease Susceptibility (Diathesis) 11/2021
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2020
1	Tuberculosis (Tuberculoses) 08/2019
1	Miliary Tuberculosis 08/2019
1	Meningitis 08/2019
1	Atrophy 01/2019
1	Chronic Hepatitis C 06/2014
1	Hepatitis 01/2013

Drug/Important Bio-Agent (IBA)

34	EpitopesIBA 01/2020 - 02/2002
25	VaccinesIBA 12/2022 - 02/2002
15	HLA-B Antigens (HLA-B)IBA 11/2021 - 12/2004
11	Proteins (Proteins, Gene)FDA Link 05/2019 - 02/2002
7	AntigensIBA 12/2022 - 12/2002
7	Peptides (Polypeptides)IBA 08/2020 - 04/2004
6	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 11/2005
6	HLA-B57 antigenIBA 01/2018 - 08/2005
6	Antiviral Agents (Antivirals)IBA 01/2018 - 06/2007
5	RNA (Ribonucleic Acid)IBA 01/2017 - 08/2005
5	LigandsIBA 11/2014 - 06/2007
5	AIDS VaccinesIBA 06/2013 - 08/2004
5	Interferon-gamma (Interferon, gamma)IBA 09/2009 - 04/2004
3	romidepsin (FK228)FDA Link 11/2022 - 01/2020
3	HLA-A Antigens (HLA-A)IBA 11/2021 - 12/2004
3	ProteomeIBA 05/2019 - 01/2008
3	Viral AntigensIBA 02/2013 - 06/2004
2	Neutralizing AntibodiesIBA 01/2022 - 02/2013
2	Viral ProteinsIBA 01/2020 - 06/2012
2	CytokinesIBA 01/2019 - 03/2015
2	Messenger RNA (mRNA)IBA 11/2018 - 08/2007
2	Amino Acids FDA Link 01/2018 - 04/2004
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 04/2008
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017 - 10/2005
2	Immunoglobulins (Immunoglobulin)IBA 01/2017 - 04/2008
2	KIR ReceptorsIBA 03/2015 - 11/2007
2	Pharmaceutical PreparationsIBA 01/2015 - 01/2009
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2013 - 03/2009
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2012 - 03/2008
2	Biomarkers (Surrogate Marker)IBA 09/2009 - 01/2008
2	Human Immunodeficiency Virus ProteinsIBA 04/2009 - 01/2007
2	Chemokine ReceptorsIBA 08/2007 - 12/2004
2	ChemokinesIBA 08/2007 - 12/2004
2	Immunodominant EpitopesIBA 04/2005 - 12/2002
1	Broadly Neutralizing AntibodiesIBA 12/2022
1	AntibodiesIBA 12/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	CC ChemokinesIBA 01/2021
1	GuanineIBA 01/2021
1	Interleukin-15 (Interleukin 15)IBA 01/2021
1	CytosineIBA 01/2021
1	Histone Deacetylase InhibitorsIBA 01/2020
1	Complement System Proteins (Complement)IBA 06/2019
1	Oxygen (Dioxygen)IBA 01/2019
1	ZincIBA 01/2019
1	Sulfates (Sulfates, Inorganic)IBA 01/2019
1	NitrogenIBA 01/2019
1	AcidsIBA 01/2017
1	MucinsIBA 01/2017
1	Granzymes (Granzyme)IBA 02/2016
1	Interleukin-22 (IL-22)IBA 03/2015
1	Interleukin-10 (Interleukin 10)IBA 03/2015
1	Interleukin-13IBA 03/2015
1	HLA-C Antigens (HLA-C)IBA 03/2015
1	PolyproteinsIBA 01/2015
1	Disulfiram (Antabuse)FDA Link 01/2015
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 08/2014
1	HLA-B*07 antigenIBA 05/2014
1	influenza matrix peptide (58-66)IBA 06/2013
1	human immunodeficiency virus p17 gag peptideIBA 06/2013
1	HIV AntigensIBA 02/2013
1	Interferon-alpha (Interferon Alfa)IBA 02/2013
1	Hepatitis B e AntigensIBA 01/2013
1	Reverse Transcriptase InhibitorsIBA 12/2012
1	NucleosidesIBA 12/2012

Therapy/Procedure

7	Therapeutics 08/2019 - 03/2007
5	Highly Active Antiretroviral Therapy (HAART) 01/2020 - 06/2007
3	Art Therapy 01/2022 - 01/2019
3	Liver Transplantation 06/2014 - 04/2008
2	Withholding Treatment 01/2020 - 01/2017
2	Drug Therapy (Chemotherapy) 09/2009 - 06/2007
1	Aftercare (After-Treatment) 01/2017
1	Immunotherapy 11/2014